Description
By Sven Agten, Ben Wu
This book provides an insider’s overview of the emerging Chinese biopharma sector, its dynamics and trends, first bust and boom cycle, long-term perspectives, and how as a foreign company or investor to tap into this. China has gone from a country with no innovation in drug discovery, to a country which starts to out-license its biopharma technology to the rest of the world. The Chinese biopharma sector is only a decade old, but it already has become a new driver of growth and value. The book takes a closer look at what drives Chinese innovation in the biopharma sector, how to deal with this innovation, and what opportunities and challenges this provides for foreign companies. The book also takes a deep dive into its first biopharma boom and bust cycle, and what it means for the sector. It also explains what deals Chinese biopharma companies and investors are looking for, what works and what doesn’t, and how as a foreign company can tap into the world’s second largest healthcare market.
Product Details
- Publisher : Palgrave Macmillan; 2024th edition (April 17, 2024)
- Language : English
- Hardcover : 162 pages
- ISBN-10 : 9819714702
- ISBN-13 : 978-9819714704
Reviews
There are no reviews yet.